Irofulven
- CAS NO.:920014-72-8
- Empirical Formula: C49H68N18O9S2
- Molecular Weight: 1117.32
- MDL number: MFCD30532719
- Update Date: 2024-11-19 20:33:22
What is Irofulven?
Absorption
Setmelanotide has a Tmax of 8 hours.
Toxicity
Data regarding overdoses of setmelanotide are not readily available. In the event of an overdose, patients should be treated with symptomatic and supportive care.
Indications
Setmelanotide is indicated for chronic weight management in patients 6 years and older with obesity due to pro-opiomelanocortin (POMC) deficiency, proprotein subtilisin/kexin type 1 (PCSK1) deficiency, or leptin receptor (LEPR) deficiency as determined by an approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance. These conditions affect the MC4R signalling pathway.
Setmelanotide is also indicated for chronic weight management in patients 6 years and older with obesity due to Bardet-Biedl syndrome.
The drug is not reported to be effective in patients with POMC, PCSK1, or LEPR variants classified as benign or likely benign, as well as other types of obesity not listed above.
Background
Setmelanotide is the first available treatment for patients with pro-opiomelanocortin, proprotein subilisin/kexin type 1, or leptin deficiencies. It is an agonist of the melanocortin 4 receptor. Earlier attempts at agonizing MC4R (such as LY2112688) lead to successful weight loss, but also an increase in blood pressure and heart rate. Other earlier treatments for these patients included gastric bypass surgery. Patients taking setmelanotide experienced an average weight loss of 0.6 kg/week.
Imcivree was granted EMA orphan designation on November 19, 2018 and FDA approval on November 25, 2020. On May 4, 2023, it was approved by Health Canada.
Pharmacokinetics
Setmelanotide agonizes MC4R, downstream of multiple potential genetic deficiencies, to induce a feeling of satiety for chronic weight management. It has a moderate duration of action as it is given daily. Patients should be counselled regarding the risk of disturbances in sexual arousal, depression and suicidal ideation, and darkening of skin pigmentation. Exercise caution in neonates and low birth weight infants, as they may experience serious adverse effects due to benzyl alcohol.
Metabolism
Setmelanotide is expected to be metabolized to small peptides and amino acids.
Properties of Irofulven
Density | 1.54±0.1 g/cm3(Predicted) |
pka | 12.82±0.70(Predicted) |
Safety information for Irofulven
Computed Descriptors for Irofulven
New Products
4-AMINO-TETRAHYDRO-PYRAN-4-CARBOXYLIC ACID HCL 4-(Dimethylamino)tetrahydro-2H-pyran-4-carbonitrile 4-AMINO-TETRAHYDRO-PYRAN-4-CARBOXYLIC ACID 4-Aminotetrahydropyran-4-carbonitrile Hydrochloride (R)-3-Aminobutanenitrile Hydrochloride 5-Bromo-2-nitropyridine Nimesulide BP Aceclofenac IP/BP/EP Diclofenac Sodium IP/BP/EP/USP Mefenamic Acid IP/BP/EP/USP Ornidazole IP Diclofenac Potassium 3-Bromopyrazole (3aR,4R,5R,6aS)-hexahydro-5-Triethyl silyloxy-4-((E)-3-oxo-5-phenylpent-1- enyl)cyclopenta[b]furan-2-one. 1-Chlorocarbonyl-4-piperidinopiperidine 1-Bromo-4-phenyl-2-Butanone 4-Amino-2-fluoro-N-methylbenzamide 1,1'-Carbonyldiimidazole SODIUM AAS SOLUTION ZINC AAS SOLUTION BUFFER SOLUTION PH 10.0(BORATE) GOOCH CRUCIBLE SINTERED AQUANIL 5 BERYLLIUM AAS SOLUTIONRelated products of tetrahydrofuran
You may like
-
Dimethyl [2-oxo-3-[3-(trifluoromethyl)phenoxy]propyl]phosphonate 99%View Details
54094-19-8 -
85-81-4 99%View Details
85-81-4 -
Cyclopentane carboxxylic acid 3400-45-1 99%View Details
3400-45-1 -
208111-98-2 (3aR,4R,5R,6aS)-5-(Benzoyloxy)hexahydro-4-[(1E)-3-oxo-4-[3-(trifluoromethyl)phenoxy]-1-buten- 1-yl]-2H-cyclopenta[b]furan-2-one 99%View Details
208111-98-2 -
2033-24-1 99%View Details
2033-24-1 -
Meldrums acid 2033-24-1 99%View Details
2033-24-1 -
Cyaclopentane carboxylic acid 99%View Details
3400-45-1 -
2-Aminopyridine 504-29-0 99%View Details
504-29-0